X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB DISHMAN PHARMA UNICHEM LAB/
DISHMAN PHARMA
 
P/E (TTM) x -276.4 25.1 - View Chart
P/BV x 2.0 3.3 60.9% View Chart
Dividend Yield % 1.3 0.7 189.0%  

Financials

 UNICHEM LAB   DISHMAN PHARMA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-17
DISHMAN PHARMA
Mar-16
UNICHEM LAB/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs320374 85.4%   
Low Rs221129 171.5%   
Sales per share (Unadj.) Rs167.2197.8 84.5%  
Earnings per share (Unadj.) Rs12.021.2 56.4%  
Cash flow per share (Unadj.) Rs16.934.7 48.8%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %1.10.8 139.6%  
Book value per share (Unadj.) Rs117.0179.9 65.1%  
Shares outstanding (eoy) m90.8880.69 112.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.61.3 127.1%   
Avg P/E ratio x22.611.9 190.6%  
P/CF ratio (eoy) x16.07.2 220.4%  
Price / Book Value ratio x2.31.4 165.2%  
Dividend payout %25.19.4 266.0%   
Avg Mkt Cap Rs m24,57820,306 121.0%   
No. of employees `0005.20.8 625.9%   
Total wages/salary Rs m2,4875,355 46.5%   
Avg. sales/employee Rs Th2,928.319,252.7 15.2%   
Avg. wages/employee Rs Th479.46,459.5 7.4%   
Avg. net profit/employee Rs Th209.42,064.1 10.1%   
INCOME DATA
Net Sales Rs m15,19515,961 95.2%  
Other income Rs m110265 41.5%   
Total revenues Rs m15,30516,226 94.3%   
Gross profit Rs m1,7884,103 43.6%  
Depreciation Rs m4521,091 41.4%   
Interest Rs m34944 3.6%   
Profit before tax Rs m1,4132,334 60.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m326624 52.2%   
Profit after tax Rs m1,0871,711 63.5%  
Gross profit margin %11.825.7 45.8%  
Effective tax rate %23.126.7 86.3%   
Net profit margin %7.210.7 66.7%  
BALANCE SHEET DATA
Current assets Rs m6,42611,018 58.3%   
Current liabilities Rs m3,9179,517 41.2%   
Net working cap to sales %16.59.4 175.6%  
Current ratio x1.61.2 141.7%  
Inventory Days Days68110 61.2%  
Debtors Days Days7735 221.0%  
Net fixed assets Rs m7,41016,304 45.4%   
Share capital Rs m182161 112.6%   
"Free" reserves Rs m10,45412,907 81.0%   
Net worth Rs m10,63614,516 73.3%   
Long term debt Rs m44,189 0.1%   
Total assets Rs m15,25829,805 51.2%  
Interest coverage x42.93.5 1,236.4%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x1.00.5 186.0%   
Return on assets %7.38.9 82.4%  
Return on equity %10.211.8 86.7%  
Return on capital %13.617.5 77.5%  
Exports to sales %24.124.8 97.3%   
Imports to sales %4.93.7 132.4%   
Exports (fob) Rs m3,6663,956 92.7%   
Imports (cif) Rs m752596 126.0%   
Fx inflow Rs m5,2984,952 107.0%   
Fx outflow Rs m0697 0.0%   
Net fx Rs m5,2984,255 124.5%   
CASH FLOW
From Operations Rs m6832,786 24.5%  
From Investments Rs m-1,316-1,529 86.0%  
From Financial Activity Rs m592-941 -62.9%  
Net Cashflow Rs m-40316 -12.6%  

Share Holding

Indian Promoters % 50.1 61.4 81.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 3.7 408.1%  
FIIs % 3.0 12.7 23.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 22.1 143.4%  
Shareholders   20,176 46,261 43.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   STRIDES SHASUN LTD  ELDER PHARMA  SUVEN LIFE  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1%

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Jun 18, 2018 03:35 PM

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - DISHMAN PHARMA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS